Johnson & Johnson $JNJ Stock: Whittier Trust Co. Raises Stake

Whittier Trust Co. raised its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 3.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 191,756 shares of the company’s stock after purchasing an additional 5,606 shares during the quarter. Whittier Trust Co.’s holdings in Johnson & Johnson were worth $50,133,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in JNJ. TIAA Trust National Association boosted its position in shares of Johnson & Johnson by 3.2% during the third quarter. TIAA Trust National Association now owns 14,108 shares of the company’s stock valued at $3,735,000 after buying an additional 432 shares during the period. Saranac Partners Ltd raised its holdings in shares of Johnson & Johnson by 82.5% in the third quarter. Saranac Partners Ltd now owns 2,942 shares of the company’s stock worth $804,000 after buying an additional 1,330 shares during the period. Patron Partners LLC raised its holdings in shares of Johnson & Johnson by 9.9% in the third quarter. Patron Partners LLC now owns 11,923 shares of the company’s stock worth $3,157,000 after buying an additional 1,074 shares during the period. Red Oak Financial Group LLC lifted its stake in shares of Johnson & Johnson by 28.5% during the 3rd quarter. Red Oak Financial Group LLC now owns 2,414 shares of the company’s stock worth $639,000 after acquiring an additional 535 shares during the last quarter. Finally, Advisors Asset Management Inc. bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $56,066,000. Institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 13,072 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at $4,832,923.66. This trade represents a 43.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.16% of the company’s stock.

Trending Headlines about Johnson & Johnson

Investors following JNJ have been watching these headlines:

  • Positive Sentiment: Phase 4 results for TREMFYA in axial psoriatic arthritis met key endpoints, with significant symptom improvement and more than twice the placebo reduction in MRI-assessed inflammation. The data could strengthen the drug’s commercial prospects. Article
  • Neutral Sentiment: JPMorgan raised its JNJ price target to $300 from $285 but kept a “neutral” rating, signaling a higher valuation estimate without a change in its overall recommendation. Analyst rating
  • Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar talc verdict and increased damages, reinforcing ongoing litigation exposure for J&J. Article

Analyst Ratings Changes

Several analysts have recently weighed in on JNJ shares. Citigroup lifted their target price on Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. Sanford C. Bernstein set a $270.00 price target on shares of Johnson & Johnson in a report on Thursday, October 15th. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a research note on Thursday, October 15th. Leerink Partners decreased their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a report on Wednesday, October 14th. Finally, Guggenheim reiterated a “buy” rating and set a $287.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $276.54.

Read Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Stock Up 1.3%

NYSE:JNJ opened at $270.54 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. Johnson & Johnson has a 1-year low of $199.90 and a 1-year high of $290.25. The company has a 50-day moving average of $267.53 and a 200 day moving average of $250.98. The firm has a market cap of $651.27 billion, a PE ratio of 40.99, a price-to-earnings-growth ratio of 2.79 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter last year, the firm posted $2.80 EPS. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.